Recent interest in Pfizer (PFE) has been driven by U.S. regulators approving IBRANCE as the first CDK4/6 inhibitor ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer today and set a price target of $28.00. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more ...

In the latest trading session, Pfizer (PFE) closed at $23.72, marking a -2.47% move from the previous day. The stock trailed ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

Healthcare has become Wall Street’s bargain bin in 2026, and value hunters are starting to pay attention. Drug pricing reform ...

Eli Lilly & Company LLY and Pfizer PFE are large-cap U.S. drugmakers supported by broad product portfolios and strong research capabilities. Lilly has emerged as a leader in cardiometabolic medicine, ...

Pfizer’s valuation story turns to pipeline progress, oncology pressure, earnings strength, and healthcare execution after a ...

SureCare Pharmacy manager Oscar Uribe shows off a package of Pfizer Paxlovid pills inside of Esperanza Health Center in Chicago on Jan. 13, 2022. Pfizer's Paxlovid is a treatment for COVID-19. (Chris ...

The U.S. Food and Drug Administration approved the use of Ibrance as maintenance treatment for adults with a specific type of advanced or metastatic breast cancer on Wednesday.

Pfizer expands its oncology portfolio after EU approval for the Keytruda and Padcev regimen, strengthening its cancer ...

After losing nearly half its value from its 2021 highs, Pfizer stock (NYSE: PFE) now trades at about $25, presenting a potentially attractive value setup. As the company continues to adapt to a ...